GeneDx Holdings (WGS) Common Equity (2020 - 2026)

GeneDx Holdings (WGS) has reported Common Equity for 7 consecutive years, with $254.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 1.27% year-over-year to $254.1 million; the TTM figure through Mar 2026 stood at $254.1 million (down 1.27% YoY), while the FY2025 annual figure was $308.2 million, up 25.66% from the prior year.
• Common Equity eased to $254.1 million in Q1 2026 per WGS's latest filing, from $308.2 million in the prior quarter.
• Across five years, Common Equity topped out at $637.3 million in Q2 2022 and bottomed at $194.0 million in Q2 2024.
• Historically, Common Equity has averaged $301.7 million across 5 years, with a median of $257.4 million in 2025.
• Annual changes were most pronounced in 2022 — Common Equity jumped 212.49% — and 2023, when it tumbled 54.7%.
• GeneDx Holdings' Common Equity stood at $253.7 million in 2022, then fell by 10.13% to $228.0 million in 2023, then advanced by 7.56% to $245.2 million in 2024, then rose by 25.66% to $308.2 million in 2025, then decreased by 17.54% to $254.1 million in 2026.
• Business Quant data shows WGS's Common Equity at $254.1 million in Q1 2026, $308.2 million in Q4 2025, and $292.3 million in Q3 2025.